

Richard J. Noveroske M.D.

3901 Lincoln Avenue
Evansville, Indiana 47715
Tel: (812) 476-7948

United States Nuclear Regulatory Commission
Region III
Radioisotope Licensing Section
799 Roosevelt Road
Glen Ellyn, Illinois 60137

Dear Sir,

I enclose three copies of Page 4, "Application for Byproduct Materials License-Medical, Supplement A-- Human Use." They are signed by my preceptors and their license numbers are included.

I received my board certification in Radiology in December 1964 as a Radiologist--certified in diagnostic, therapeutic, nuclear medicine, and physics portions of the board.


I took my residency in radiology at the Indiana University Medical Center from July 1, 1959 to June 30, 1962. The director of the program was Doctor John A. Campbell.

I spent about 200 hours in class work and working with instruments as a resident under the direction of Dr. Campbell, Dr. Felix Pircher and the staff physicist. The classroom work included lectures in physics, instruments, radiation biology, radiation protection etc.

I would like to get licensed under the license being applied for by Daviess County Hospital, Washington, Indiana. The license is a renewal of their present license which is number: 13-16,38-01. This would help the hospital, the present radiologist and me.

If you need more information, call or write me at the above telephone or address.

Sincerely yours,


R.J. Noveroske

Enclosures: Preceptor Forms.

8507260563 850709
REG3 LIC30
13-16138-01 PDR

8(5-8-79)

APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL SUPPLEMENT A—HUMAN USE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
Tc-99m	Placenta localization	0	0
	Liver and spleen imaging	0	0
	Lung imaging	0	0
	Bone imaging	0	0
Xe-133	Blood flow studies and pulmonary function studies	0	0
Se-75	Pancreas imaging	0	0
P-32	Treatment of polycythemia, leukemia, and Bone metastases	3	4
	Intracavitary treatment	3	0
I-131	Treatment of thyroid carcinoma	0	0
	Treatment of hyperthyroidism and cardiac condition	2	2
Au-198	Intracavitary treatment	3	0
Co-60 or CO-137	Interstitial treatment	0	0
	Intracavitary treatment	5	2
Ir-192	Interstitial treatment	0	0
Co-60 CO-137	Teletherapy treatment	50	50
Sr-90	Treatment of eye disease	2	2

Key to Column (C) and (D) above:

1. Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
2. Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed; (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data; and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

12. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING July 1962- April 1964 200 hours.

13. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF ARTHUR A. HUBB, JR., D.O.

Dr. Arthur A. Hubb, Jr.
1001 Mary Street

AT 1001 Mary Street, St. Louis, Mo. 63101

(Institution) Name and Address

3-60740-01

(Byproduct Material License Number)

Arthur A. Hubb, Jr.

(Signature of Preceptor)

875-879

UNITED STATES ATOMIC ENERGY COMMISSION
APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Page 2 may be used for comments and additional information.

10. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code)

Richard J. Nevers
3401 Lincoln Avenue, Joliet, Illinois 61775

11. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 10 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131 or I-125	Diagnosis of thyroid function	100	100
	Determination of blood and blood plasma volume	5	5
	Liver function studies	0	0
	Fat absorption studies	0	0
	Kidney function studies	0	0
	In vitro studies	0	0
Cr-51	Gastrointestinal protein loss studies	0	0
	Determination of red blood cell volume and studies of red blood cell survival	2	2
Fe-59	Iron turn over studies	0	0
Co-58 or Co-60	Intestinal absorption studies	10	5
K-42	Potassium space determinations	0	0
I-131	Thyroid imaging	50	25
	Brain tumor localization and cardiac imaging	0	0
	Cisternography	0	0
	Lung imaging	0	0
	Liver imaging	0	0
	Kidney imaging	0	0
	Placenta localization	0	0
Cr-51	Placenta localization	0	0
	Spleen imaging	1	0
Au-198	Liver Imaging	0	0
Hg-197	Brain imaging	0	0
	Kidney imaging	6	15
Hg-203	Brain imaging	11	1
Sr-85	Bone imaging	0	0
Tc-99m	Brain imaging	0	0
	Thyroid imaging	0	0
	Salivary gland imaging	0	0
	Blood pool imaging	0	0

UNITED STATES ATOMIC ENERGY COMMISSION
APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Page 2 may be used for comments and additional information.

10. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code)

Richard John Noveroske
3901 Lincoln Avenue, Evansville, Indiana 47715

11. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 10 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131 or I-125	Diagnosis of thyroid function	5	15
	Determination of blood and blood plasma volume	0	0
	Liver function studies	0	0
	Fat absorption studies	0	0
	Kidney function studies	0	0
	In vitro studies	0	0
Cr-51	Gastrointestinal protein loss studies	0	0
	Determination of red blood cell volume and studies of red blood cell survival	0	0
Fe-59	Iron turn over studies	0	0
Co-58 or Co-60	Intestinal absorption studies	0	0
K-42	Potassium space determinations	0	0
I-131	Thyroid imaging	5	15
	Brain tumor localization and cardiac imaging	0	0 1/mg
	Cisternography	0	0
	Lung imaging	0	0
	Liver imaging	0	0
	Kidney imaging	0	0
	Placenta localization	0	0 2/mg
Cr-51	Placenta localization	0	0
	Spleen imaging	0	0 1/mg
Au-198	Liver imaging	0	0
Hg-197	Brain imaging	0	0
	Kidney imaging	0	0
Hg-203	Brain imaging	0	0
Si-85	Bone imaging	0	0
Tc-99m	Brain imaging	20	50
	Thyroid imaging	0	0
	Salivary gland imaging	0	0
	Blood pool imaging	0	0

APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL

SUPPLEMENT A—HUMAN USE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
Tc-99m	Placenta localization	0	0
	Liver and spleen imaging	10	30
	Lung imaging	10	30
	Bone imaging	0	0 4/10
Xe-133	Blood flow studies and pulmonary function studies	0	0
Se-75	Pancreas imaging	0	0
P-32	Treatment of polycythemia, leukemia, and Bone metastases	0	0
	Intracavitary treatment	0	0
I-131	Treatment of thyroid carcinoma	0	0
	Treatment of hyperthyroidism and cardiac condition	1	0
Au-198	Intracavitary treatment	0	0
Co-60 or CO-137	Interstitial treatment	0	0
	Intracavitary treatment	0	0
Ir-192	Interstitial treatment	0	0
Co-60 CO-137	Teletherapy treatment	20	50
Sr-90	Treatment of eye disease	0	0

Key to Column (C) and (D) above

- 1 Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
- 2 Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed, (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data, and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

12. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING: 1 Jan 1974 to 30 June 1975; 400 hours

13. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF: Mina K. Edelman, M.D.

St. Mary's Hospital
400 North Pleasant Avenue
Centralia, Illinois 62801

At

(Institution) Name and Address

(Byproduct Material License Number)

(Signature of Preceptor)

8/5-8-79

UNITED STATES ATOMIC ENERGY COMMISSION
APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL
SUPPLEMENT A—PRECEPTOR STATEMENT

This page is to be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each. Page 2 may be used for comments and additional information.

10. NAME AND ADDRESS OF APPLICANT PHYSICIAN (Include ZIP Code)
Richard John Noveroske, 3901 Lincoln Avenue
Evansville, Indiana 47715

11. CLINICAL TRAINING AND EXPERIENCE OF PHYSICIAN NAMED IN ITEM 10 ABOVE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
I-131 or I-125	Diagnosis of thyroid function	43	31
	Determination of blood and blood plasma volume	1	1
	Liver function studies	0	0
	Fat absorption studies	0	0
	Kidney function studies	0	0
	In vitro studies	0	0
Cr-51	Gastrointestinal protein loss studies	0	0
	Determination of red blood cell volume and studies of red blood cell survival	1	2
Fe-59	Iron turn over studies	0	0
Co-58 or Co-60	Intestinal absorption studies	0	0
K-42	Potassium space determinations	0	0
I-131	Thyroid imaging	1	0
	Brain tumor localization and cardiac imaging	1	0
	Cisternography	0	0
	Lung imaging	0	0
	Liver imaging	0	0
	Kidney imaging	0	0
	Placenta localization	0	0
Cr-51	Placenta localization	0	0
	Spleen imaging	0	0
Au-198	Liver imaging	0	0
Hg-197	Brain imaging	0	0
	Kidney imaging	0	0
Hg-203	Brain imaging	0	0
Sr-85	Bone imaging	0	0
Tc-99m	Brain imaging	0	0
	Thyroid imaging	0	0
	Salivary gland imaging	0	0
	Blood pool imaging	0	0

87-5-8-79

APPLICATION FOR BYPRODUCT MATERIAL LICENSE—MEDICAL

SUPPLEMENT A—HUMAN USE

(A) ISOTOPE	(B) CONDITIONS DIAGNOSED OR TREATED	(C) No. Cases Observed (See 1 in key below)	(D) No. Cases Involving Personal Participation (See 2 in key below)
Tc-99m	Placenta localization	0	0
	Liver and spleen imaging	0	0
	Lung imaging	0	0
	Bone imaging	0	0
Xe-133	Blood flow studies and pulmonary function studies	0	0
Se-75	Pancreas imaging	0	0
P-32	Treatment of polycythemia, leukemia, and Bone metastases	1	1
	Intracavitary treatment		
I-131	Treatment of thyroid carcinoma	1	0
	Treatment of hyperthyroidism and cardiac condition	7	1
Au-198	Intracavitary treatment	0	1
Co-60 or Co-137	Interstitial treatment	0	0
	Intracavitary treatment	0	0
Ir-192	Interstitial treatment	0	0
Co-60 Co-137	Teletherapy treatment	20	40
Sr-90	Treatment of eye disease	0	0

Key to Column (C) and (D) above

1. Observation should consist of observing radioisotope administration techniques and discussion with preceptor the case histories to establish most appropriate diagnostic and/or therapeutic procedure, limitation, contraindications, etc.
2. Personal participation should consist of (a) supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation on dosage to be prescribed, (b) collaboration in calibration of the dose and the actual administration of the dose to the patient, including calculation of the radiation dose, related measurements, and plotting of data, and (c) adequate period of training to enable the physician to manage radioactive patients and to follow patients through diagnosis and/or the course of treatment.

12. DATES AND TOTAL NUMBER OF HOURS OF CLINICAL RADIOISOTOPE TRAINING January 1961-April 1962 270 Hours.

13. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF Dr. John A. Campbell, M.D.

Department of Radiology
Indiana University Medical Center.

AT

(Institution Name and Address)

(Byproduct Material License Number)

1100 West Michigan Street
Indianapolis, Indiana

John A. Campbell M.D.
(Signature of Preceptor)

8/5-8-73

The following information concerns the Preceptors of Dr. Glenn Ross M.D., who is one of the physicians listed on our "License Renewal".

Dr. Glenn Ross M.D. attended a Nuclear Medicine program under Dr. Bruce Sedee in Cleveland, Ohio in 1974, for the purpose of training Radiologists in the proper uses and handling of materials and equipment necessary to direct a Nuclear Medicine department.

Dr. Glenn Ross M.D. is presently on our "Byproduct Materials License-Medical" as the director of the department.

The program Dr. Ross attended has now disbanded and ceases to function. It would be extremely difficult to get the signatures of his preceptors in addition to his hours in each category.

I called the United States Nuclear Regulatory Commission and spoke to their representative concerning this matter. He assured me that I could include a copy of this information as it applied to the last license, since it included the necessary information and signatures.

This information is attached. Our present License number is: 13-16138-01

Dr. Ross and I will be available for any questions. We may be reached at the following telephone: (812) 254 2760 Dr. Ross will be in the Radiology department and I will be in the Nuclear Medicine department.

Respectfully,

Richard D. Smith

Mr. Richard D. Smith R.T.